Imclone Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: Bridgewater NJ United States (1984)
Status: Acquired by Eli Lilly (2008)

Organization Overview

First Clinical Trial
1998
NCT00037713
First Marketed Drug
2004
cetuximab (erbitux)
First NDA Approval
2004
cetuximab (erbitux)
Last Known Activity
2011

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

IMCLONE | ImClone LLC

Indications

Approved Indications


 

Colorectal Neoplasms

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Carcinoma (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Carcinoma, Small Cell (Phase 3)

Carcinoma, Squamous Cell (Phase 2)

Colonic Neoplasms (Phase 2)

Colorectal Neoplasms (Phase 3)

Disease Progression (Phase 2)

Fallopian Tube Neoplasms (Phase 2)

Glioblastoma (Phase 2)

Head and Neck Neoplasms (Phase 2)

Hodgkin Disease (Phase 3)

Leiomyosarcoma (Phase 2)

Leukemia (Phase 1)

Leukemia, Myeloid (Phase 1)

Lung Neoplasms (Phase 3)

Lymphoma (Phase 3)

Melanoma (Phase 1)

Neoplasm Metastasis (Phase 2)

Neoplasms (Phase 2)

Neoplasms, Squamous Cell (Phase 2)

Neuroectodermal Tumors (Phase 2)

Neuroectodermal Tumors, Primitive (Phase 2)

Neuroectodermal Tumors, Primitive, Peripheral (Phase 2)

Ovarian Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 2)

Peritoneal Neoplasms (Phase 2)

Prostatic Neoplasms (Phase 2)

Rectal Neoplasms (Phase 2)

Rhabdomyosarcoma (Phase 2)

Sarcoma (Phase 2)

Sarcoma, Ewing (Phase 2)

Sarcoma, Synovial (Phase 2)

Small Cell Lung Carcinoma (Phase 3)

Squamous Cell Carcinoma of Head and Neck (Phase 2)

Stomach Neoplasms (Phase 2)

Urinary Bladder Neoplasms (Phase 2)

Uterine Cervical Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 59
  • # of Trial APIs: 30